«Защищенные» аминопенициллиныпри лечении внебольничной пневмонии и ее осложнений

1. Ferech M, Coenen S, Dvorakova K et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient penicillin use in Europe. J Antimicrob Chemother 2006; 58 (2): 408–12.
2. Рачина С.А., Зайцев А.А. Фармакоэпидемиологические исследования антибактериальных препаратов при внебольничных инфекциях дыхательных путей. Внебольничные инфекции дыхательных путей: диагностика и лечение. Руководство для врачей. М.: ООО «М-Вести», 2008; 254–71.
3. Рачина С.А., Фокин А.А., Ишмухаметов А.А. и др. Анализ динамики поквартального потребления антибактериальных препаратов для системного применения в амбулаторном и госпитальном секторах в РФ в 2004 году. Ремедиум 2006; 11: 24–9.
4. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature 1940; 373: 837.
5. Du Bois SK, Marriott MS, Amyes SG. TEM- and SHV-derived extended-spectrum β-lactamases: relationship between selection, structure and function. J Antimicrob Chemother 1995; 35: 7–22.
6. Reading C, Cole M. Ctavulanic acid: a beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother 1977; 11 (5): 852–7.
7. Bush K, Jacoby GA, Medeiros AA. Functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211–33.
8. Chambers HF. Other beta-lactam antibiotics. In: Mandell GL, Bennet JE, Dolin R, editors. Principles and Practice of Infectious Diseases. Churchill Livingstone. 2004: 311–8.
9. Cooper CE, Slocombe B, White AR. Effect of low concentrations of clavulanic acid on the in vitro activity of amoxycillin against β-lactamase producing Branhamella catarrhalis and Haemophilus influenzae. J Antimicrob Chemother 1990; 26: 371–80.
10. Neu HC, Wilson APR. Gruneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother 1993; 5: 67–93.
11. Drugs in pregnancy and lactation. Eds. CG.Briggs, RK.Freeman, SJ.Yaffe. Williams & Wilkins, 1994.
12. Berkovitch M, Diav-Citrin O, Greenberg R et al. First-trimester exposure to amoxycillin/clavulanic acid: a prospective, controlled study. Br J Clin Pharmacol 2004; 58 (3): 298–302.
13. Quenzer RW, Pettit KG, Arnold RJ, Kaniecki DJ. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection. Am J Manag Care 1997; 37: 1027–36.
14. Ramirez JA. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis 1995; 22: 219–23.
15. Calvo A, Amores R, Valero E et al. Activity of different antimicrobial agents against penicillin-resistant Streptococcus pneumoniae. Rev Esp Quimioter 2001; 14: 345–50.
16. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999–2005 гг.: результаты многоцентровых проспективных исследований Пегас I и Пегас II. Клин. микробиол. антимикроб. химиотер. 2006; 8 (1): 33–47.
17. Bush K. The evolution of β-lactamases. Antibiotic Resistance: Origins, Evolution, Selection and Spread. John Willey & Sons 1997: 152–69.
18. Thornsberry C, Sahm DF, Kelly LJ et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000. Clin Infect Dis 2002; 34 (Suppl. 1): 4–16.
19. Jacobs MR, Felmingham D, Appelbaum PC et al. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52 (2): 229–46.
20. Lister PD, Gardner VM, Sanders CC. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cehalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrob Agents Chemother 1999; 43: 882–9.
21. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. М.: OOO «Издательский дом «М-Вести», 2006.
22. Menendez R, Torres A, Zalacain R et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59: 960–5.
23. Синопальников А.И., Андреева И.В., Стецюк О.У. Пневмонии в домах престарелых: современный взгляд на проблему. КМАХ 2007; 9 (1): 4–19.
24. Mylotte JM. Nursing home-acquired pneumonia: update on treatment options. Drugs Aging 2006; 23: 377–90.
25. Chu JE. Anaerobic pulmonary infections. Manual of clinical problems in pulmonary medicine. Eds. RA.Bordow, AL.Ries, TA.Morris. Philadelphia: Lippincott Williams & Wilkins, 2001: 135–40.
26. Bartlett J. Management of respiratory tract infections. Philadelphia: Lippincott Williams & Wilkins, 2001.
27. Страчунский Л.С., Козлов С.Н. Современная антимикробная химиотерапия. Руководство для врачей. М.: Боргес, 2002.
28. Bartlett JG, Thadepalli H, Gorbach SL, Finegold SM. Bacteriology of empyema. Lancet 1999; 2: 338–40.